In 2014, MAPS spun out a individual division to direct analysis and prepare for an eventual FDA software, which it submitted at the end of previous year. In early 2024, that offshoot was renamed Lykos Therapeutics.Fears about security issues, Negative effects, and abuse are very likely to pop up for other psychedelics as well, states Mason Marks, w